




David Miklos

James and Katherine Lau Professor

Medicine - Blood & Marrow Transplantation

 NIH Biosketch available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic G

MC 6555

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 498-6159

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

Kimberly Baker - Administrative Associate

Email kbaker5@stanford.edu

Tel 650-725-5949

Bio

BIO

I am the Chief of Stanford BMT and Cell Therapy Program that provides 750 cancer cell therapies annually. Our BMT-CT research fosters the development of both laboratory immunologists, and clinical translational researchers. Our allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cures blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Our CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. Our goal is to combine graft engineered allogeneic HCT with CAR-T benefit.

The Miklos lab pioneered protein microarray technologies to discover clinically relevant allogeneic antibodies. Our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. More recently, our team developed human correlative assays to optimize CAR-T therapy including ctDNA MRD, flow cytometry tumor antigen quantification, Immune phenotype CAR-T characterization (CAR-FACS), and single cell RNA characterization of CAR-T cells.

Immunotherapy is revolutionizing cancer treatment and Stanford Cancer Cell Therapy Program is developing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD20, CD22, CD79A, and BCMA.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Chimeric Antigen Receptor Therapy (CAR-T)
- Blood and Marrow Transplantation
- Graft vs Host Disease
- Lymphoma
- Leukemia

- Multiple Myeloma
- Hematology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Chief BMT and Cell Therapy Program, Stanford University, (2020- present)
- Associate Chief Blood and Marrow Transplantation, Stanford University, (2020-2020)
- Clinical Director Cancer Cell Therapy, Stanford University, (2016-2022)
- Medical Director of Stanford Cellular Therapeutics and Transplantation Laboratory, Stanford University, (2011-2016)

HONORS AND AWARDS

- Phi Beta Kappa, University of Notre Dame (1987)
- Alpha Omega Alpha, Yale Medical School (1995)
- Predoctoral Fellow, Howard Hughes Medical Institute (1989-1993)
- Medical Scientist Training Fellow, NIH (1993-1995)
- Clinical Investigator Training Program Scholar, Harvard Medical School (2001-2003)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Transplantation and Cell Therapy (1998 - present)
- Member, American Society of Clinical Oncology (2014 - present)
- Member, American Society of Hematology (1998 - present)

PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2019)
- Board Certification, American Board of Internal Medicine , Hematology (2019)
- Medical Education: Yale University Office of the Registrar (1995) CT
- Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2001) MA
- Residency: Brigham and Women's Hospital Harvard Medical School (1998) MA
- Internship: Brigham and Women's Hospital Harvard Medical School (1996) MA
- B.S., University of Notre Dame (1987)
- M.D., Yale University Medical School (1995)
- Ph.D., Yale University , Genetics (1995)

LINKS

- Bone Marrow Transplantation Site: <http://bmt.stanford.edu>
- CAR-T patient video: <https://www.youtube.com/watch?v=-sfPudGvOXA>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>
- Stanford Yescarta research FDA approval: <https://stanfordhealthcare.org/stanford-health-care-now/2017/car-t-therapy.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Miklos is a seasoned hematopoietic cell transplant (HCT) clinician and immunologist with special interest in B cell biology, tumor immunology and graft versus host disease (GVHD). His Stanford laboratory has applied cutting edge technologies to human translational research including: protein microarrays for antibody identification, antigen specific B cell identification, and next-generation deep sequencing of B and T lymphocyte cell receptors for monitoring cancer and immune responses. He has translated his laboratory insights to improve allogeneic hematopoietic cell transplantation, and his research significantly contributed to two 2017 FDA approvals: 1) Yescarta for patients with aggressive lymphoma that has failed two therapies, 2) Ibrutinib for patients with cGVHD that has failed prior therapy

Ongoing CAR-T human correlative research:

1) Phase I CAR19-22 Safety and efficacy outcomes – the first bispecific CAR-T study for patients with rel/refractory DLBCL and ALL, 2) CAR19 CD4-CD8 immune phenotyping of DLBCL patients receiving CA-T; Hypothesize: Real-time CAR-T characterization predicts toxicity. 3) Mechanisms for DLBCL treatment Failure following CAR19 – CD19 Antigen loss accounts for 25% treatment failure. 4) Single cell RNA analysis of CAR-19 T cells in DLBCL lymph nodes following CAR-T – cell fate mapping via TCR analysis

CLINICAL TRIALS

- EAP for Subjects Receiving Lisocabtagene Maraleucl That is Nonconforming for Commercial Release, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- LTFU in Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells, Recruiting
- Phase 1/2 KITE-363 / KITE-753 Autologous Anti-CD19/CD20 CAR T-Cell Therapies in R/R B-Cell Lymphoma, Recruiting
- Phase I B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme, Recruiting
- Phase II Anti-CD20 & Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and/or Refractory DLBCL, Recruiting
- Phase tbd Optimizing ctDNA-Based MRD Assessment in DLBCL, MCL, & FL Undergoing CAR Therapy, Recruiting
- Protocol for Research DB for HCT, Other Cellular Therapies and Marrow Toxic Injuries, Recruiting
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease, Not Recruiting
- CTL019 Out of Specification MAP for ALL or DLBCL Patients, Not Recruiting
- Expanded Access Axicabtagene Ciloleucl in Tx Relapsed/Refractory T-plant-Ineligible Aggressive NHL, Not Recruiting
- Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- LTFU in Adicet Bio Allogeneic Gamma Delta T Cell Investigational Products, Not Recruiting
- Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD, Not Recruiting
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD, Not Recruiting
- Phase I ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta T Cells in B Cell Malignancies, Not Recruiting
- Phase I ALLO-501 & ALLO-647 in Relapsed/Refractory Large B-Cell or Follicular Lymphoma, Not Recruiting
- Phase I Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease , Not Recruiting
- Phase I Primary T Regulatory Cell Tx to Treat Visceral Acute GVHD After HCT, Not Recruiting
- Phase I Study of FT819 in B-cell Malignancies, Not Recruiting
- Phase I/II ALLO-501A Anti-CD19 Allogenic Car-T Cell Tx & ALLO-647 Anti-CD52 Mab in R/R LBCL, Not Recruiting
- Phase I/II Axicabtagene Ciloleucl in Combo w/ Utomilumab in Relapsed/Refractory LargeB-CellLymphoma, Not Recruiting
- Phase I/II bbT369 Dual Targeting CAR TCell DrugProduct w/ Gene Edit in Relapsed/Refractory BCell NHL, Not Recruiting

- Phase I/II KTE-C19 in Combo w/ Atezolizumab in Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Phase I/II KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma, Not Recruiting
- Phase I/IIa PBCAR20A in Relapsed/Refractory (R/R) NHL or R/R CLL or Small Lymphocytic Lymphoma, Not Recruiting
- Phase Ib Axicabtagene Ciloleucl Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHL, Not Recruiting
- Phase Ib Tisagenlecleucl in Combo w/ Ibrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Not Recruiting
- Phase Ib/2 Ibrutinib in Steroid Dependent or Refractory Chronic GVHD, Not Recruiting
- Phase II Ibrutinib Maintenance After Reduced-Intensity Conditioning &Allogeneic HCT in AcuteLeukemia, Not Recruiting
- Phase II Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic HCT, Not Recruiting
- Phase II KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma, Not Recruiting
- Phase II Lisocabtagene Maraleucl (JCAR017) in 2nd-Line Therapy in Adult Aggressive B-cell NHL, Not Recruiting
- Phase II Obinutuzumab in Prevention of cGVHD After Allogeneic Peripheral Blood Stem Cell Transplant, Not Recruiting
- Phase II Optimizing Post-Allogeneic HCT Outcomes in Lymphoma Using Ibrutinib, Not Recruiting
- Phase III Axicabtagene Ciloleucl vs SoC Therapy in Relapsed/Refractory Diffuse Large BCell Lymphoma, Not Recruiting
- PhaseI CD19/CD22 ChimericAntigenReceptor TCells+/-NKTR-255 in Recurrent/Refractory BCellMalignancies, Not Recruiting
- Pilot 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma, Not Recruiting
- Pilot Study of Imatinib in Steroid Refractory Chronic Graft Versus Host Disease, Not Recruiting
- Prospective Cohort Biomarker Eval Predicting Risk of Complications & Mortality After Allogeneic HCT, Not Recruiting
- Study of Brexucabtagene Autoleucl (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2), Not Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Not Specified

Teaching

STANFORD ADVISEES

Med Scholar Project Advisor

Nadia Kirmani

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Immunology (Phd Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Cutler, C., Kim, H. T., El Banna, H., Halloran, E., Matozel, E., Ho, V. T., Koreth, J., Gooptu, M., Shapiro, R., Kelkar, A., Gibson, C., Nikiforow, S., Nageshwar, et al
2026: JCO2503104
- **Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.** *Journal of hematology & oncology*
Muñoz, J., Locke, F. L., Reagan, P. M., Goy, A., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Flinn, I. W., Miklos, D. B., Pagel, J. M., Kersten, M. J., Forcade, E., Topp, et al
2026
- **Who Is Eligible for CAR T-Cell Therapy? Expert Perspectives on Overcoming Referral Barriers.** *Transplantation and cellular therapy*

Shadman, M., Ahmed, S., Byrne, M. T., Chavez, J. C., Kamdar, M., Sorror, M. L., Perales, M., Hill, J. A., Moslehi, J., Miklos, D. B.
2025

- **CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.** *Research square*
Hamilton, M. P., Phillips, N., Noordenbos, T., Boegeholz, J., Sugio, T., Sworder, B. J., Alig, S. K., Good, Z., Schroers-Martin, J. G., Tamaresis, J., Esfahani, M. S., Lu, Y., Olsen, et al
2025
- **Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.** *Targeted oncology*
Miklos, D. B., Riedell, P. A., Bokun, A., Chavez, J. C., Schuster, S. J.
2025
- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
2025; 16 (1): 1824
- **Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma.** *Transplantation and cellular therapy*
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Lekakis, L. J., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Kersten, M. J., Zheng, Y., Zhang, et al
2024
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.** *The New England journal of medicine*
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., Frank, M. J., Sahaf, B., Mackall, et al
2024; 390 (22): 2047-2060
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **Long-Term Clinical Outcomes and B Cell Immune Reconstitution following Allo-HCT with Prophylactic, Post-Transplant Rituximab.** *Transplantation and cellular therapy*
Kennedy, V. E., Sahaf, B., Wu, F., Ehlinger, Z. J., Arai, S., Miklos, D. B.
2024
- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
- **Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium**
Spiegel, J. Y., Jain, M. D., Nastoupil, L. J., Tamaresis, J., Ghobadi, A., Lin, Y., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Dorritie, K., Sehgal, et al
AMER SOC HEMATOLOGY.2023
- **Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial**
Cutler, C., Kim, H. T., El Banna, H., Halloran, E., Matozel, E., Ho, V., Koreth, J., Gooptu, M., Shapiro, R. M., Kelkar, A. H., Gibson, C., Reynolds, C., Ansuinelli, et al
AMER SOC HEMATOLOGY.2023

- **Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection**
Ananth, S., Su, Y., Hamilton, M. P., Agarwal, N., Weng, W., Dahiya, S., Bharadwaj, S., Mallampet, J., Smith, M., Kong, K., Twoy, A., Miklos, D. B., Frank, et al
AMER SOC HEMATOLOGY.2023
- **Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma.** *Hematology/oncology clinics of North America*
Hamilton, M. P., Miklos, D. B.
2023
- **Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.** *JOURNAL OF CLINICAL ONCOLOGY*
Westin, J., Oluwole, O. O., Kersten, M., Miklos, D., Perales, M., Ghobadi, A., Rapoport, A., Sureda, A., Jacobson, C., Farooq, U., van Meerten, T., Ulrickson, M. L., Elsayy, et al
2023; 41 (17_SUPPL): LBA107
- **Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.**
Westin, J., Oluwole, O. O., Kersten, M., Miklos, D., Perales, M., Ghobadi, A., Rapoport, A., Sureda, A., Jacobson, C., Farooq, U., van Meerten, T., Ulrickson, M. L., Elsayy, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.** *Cancer cell*
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Shahrokh Esfahani, M., Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M., Spiegel, et al
2022
- **Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy** *NATURE MEDICINE*
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., Desai, M. H., Reynolds, W. D., Lin, A., Vandris, P., Wu, F., Prabhu, S., Hamilton, et al
2022
- **Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.** *Nature medicine*
Scholler, N., Perbost, R., Locke, F. L., Jain, M. D., Turcan, S., Danan, C., Chang, E. C., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., Lekakis, L. J., Lin, Y., Ghobadi, et al
2022
- **Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.** *The New England journal of medicine*
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M., Kersten, M., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., Munoz, J., Farooq, U., van Meerten, et al
2021
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021
- **Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Frank, M. J., Hossain, N. M., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I., Jacob, A. P., Mullins, C. D., Lee, L. W., Kong, K. A., Craig, J., Mackall, et al
2021: JCO2100377
- **CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.** *Blood*
Plaks, V., Rossi, J. M., Chou, J., Wang, L., Poddar, S., Han, G., Wang, Z., Kuang, S., Chu, F., Davis, R. E., Vega, F., Bashir, Z., Jacobson, et al
2021
- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al

LIPPINCOTT WILLIAMS & WILKINS.2021

- **Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).**
Jacobson, C. A., Locke, F., Hu, Z., Siddiqi, T., Ahmed, S., Ghobadi, A., Miklos, D., Lin, Y., Perales, M., Lunning, M., Herr, M., Hill, B. T., Ganguly, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.**
Tees, M., Neelapu, S., Hari, P., Mailankody, S., Miklos, D., Locke, F., Nath, R., Prashad, S., Zhou, X., Demirhan, E., Nandakumar, S., Fisher, D., Opiteck, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.** *Blood advances*
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143-155
- **Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel.** *Blood*
Spiegel, J. Y., Dahiya, S., Jain, M. D., Tamaresis, J. S., Nastoupil, L., Jacobs, M. T., Ghobadi, A., Lin, Y., Lunning, M., Lekakis, L. J., Reagan, P., Oluwole, O. O., McGuirk, et al
2020
- **Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.** *Blood advances*
Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., Sherman, M., Better, M., Go, et al
2020; 4 (19): 4898–4911
- **Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., Oluwole, O., McGuirk, J., Deol, et al
2020: JCO1902104
- **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
2020
- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy** *LEUKEMIA & LYMPHOMA*
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.
2019; 60 (2): 503-506
- **A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation.** *Haematologica*
Paul, J., Nakasone, H., Sahaf, B., Wu, F., Wang, K., Ho, V., Wu, J., Kim, H., Blazar, B. R., Ritz, J., Howard, A., Cutler, C., Miklos, et al
2019
- **Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial** *LANCET ONCOLOGY*
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, et al
2019; 20 (1): 31–42
- **Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.** *The Lancet. Oncology*
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, et al
2018
- **Updated Results of a Phase 1b/2 Study of Ibrutinib in Chronic Graft Versus Host Disease After Failure of Prior Therapy**

Waller, E. K., Miklos, D., Cutler, C. S., Arora, M., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Dubovsky, J., Chang, S., Clow, F., Lal, et al

NATURE PUBLISHING GROUP.2018: 71-73

- **Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.** *Leukemia & lymphoma*
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., Miklos, D. B.
2018: 1–4
- **Ibrutinib for chronic graft-versus-host disease after failure of prior therapy** *BLOOD*
Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Blazar, B. R., Li, Y., Chang, S., Lal, et al
2017; 130 (21): 2243–50
- **Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.** *Blood*
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., Brown, J. R., Dyer, M. J., Mato, A. R., Keating, M. J., Jaglowski, S., Clow, F., Rezvani, et al
2016
- **Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans** *BLOOD*
Nakasone, H., Tian, L., Sahaf, B., Kawase, T., Schoenrock, K., Perloff, S., Ryan, C. E., Paul, J., Popli, R., Wu, F., Otani, J. M., Collier, J., Warren, et al
2015; 125 (20): 3193-3201
- **Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia** *LEUKEMIA*
Logan, A. C., Zhang, B., Narasimhan, B., Carlton, V., Zheng, J., Moorhead, M., Krampf, M. R., Jones, C. D., Waqar, A. N., Faham, M., Zehnder, J. L., Miklos, D. B.
2013; 27 (8): 1659-1665
- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaeffer, J., Brown, et al
2012; 119 (25): 6145-6154
- **High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Logan, A. C., Gao, H., Wang, C., Sahaf, B., Jones, C. D., Marshall, E. L., Buno, I., Armstrong, R., Fire, A. Z., Weinberg, K. I., Mindrinos, M., Zehnder, J. L., Boyd, et al
2011; 108 (52): 21194-21199
- **Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission** *45th Annual Meeting and Exhibition of the American Society of Hematology*
Miklos, D. B., Kim, H. T., Miller, K. H., Guo, L. X., Zorn, E., Lee, S. J., Hochberg, E. P., Wu, C. J., Alyea, E. P., Cutler, C., Ho, V., Soiffer, R. J., Antin, et al
AMER SOC HEMATOLOGY.2005: 2973–78
- **Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.** *American journal of hematology*
Lunning, M. A., Wang, H. L., Hu, Z. H., Locke, F. L., Siddiqi, T., Jacobson, C. A., Ahmed, S., Miklos, D. B., Lin, Y., Hill, B. T., Ghobadi, A., Neelapu, S. S., Westin, et al
2024
- **CCL8/CCL13-producing tumor-associated macrophages linked to poor outcomes after CAR T cell therapy for LBCL** *American Society of Hematology*
Mo, K. C., Yeh, C. Y., Hamilton, M. P., Spiegel, J., Desai, M., Ehlinger, Z., Reynolds, W. D., Yang, E., Ozawa, M. G., Chen, Y., Prabhu, S., Frank, M. J., Muffly, et al
2024
- **Axicabtagene Ciloleucel in Combination With the 4-1BB Agonist Utomilumab in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results From ZUMA-11.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Jain, M. D., Miklos, D. B., Jacobson, C. A., Timmerman, J. M., Sun, J., Nater, J., Fang, X., Patel, A., Davis, M., Heeke, D., Trinh, T., Mattie, M., Neumann, et al
2023

- **Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*
Younes, S., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D., Johnsrud, A., Majzner, R. G., Miklos, D. B., Frank, M. J., Natkunam, Y.
2023: 100256
- **Survival with Axicabtagene Ciloleucl in Large B-Cell Lymphoma.** *The New England journal of medicine*
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M. A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., van Meerten, T., Ulrickson, M., Elsayy, et al
2023
- **Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucl in Large B-cell Lymphoma.** *Blood advances*
Dean, E. A., Kimmel, G. J., Frank, M. J., Bukhari, A., Hossain, N. M., Jain, M. D., Dahiya, S., Miklos, D. B., Altrock, P. M., Locke, F. L.
2023
- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.** *Blood*
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
2023
- **5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucl in Refractory Large B-Cell Lymphoma (ZUMA-1).** *Blood*
Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, et al
2023
- **Brexucabtagene Autoleucl for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., Mcguirk, J. P., Vose, J. M., Goy, A., Andreadis, et al
2023: JCO2201797
- **Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Miklos, D. B., Abu Zaid, M., Cooney, J. P., Albring, J. C., Flowers, M., Skarbniak, A. P., Yakoub-Agha, I., Ko, B., Bruno, B., Waller, E. K., Yared, J., Sohn, S. K., Bulabois, et al
2023: JCO2200509
- **PROTEOMIC PROFILING IN BLOOD IDENTIFIES NOVEL PRETREATMENT AND MECHANISTIC MARKERS RELATED TO INFLAMMATORY ADVERSE EVENTS IN RELAPSED/ REFRACTORY LARGE B-CELL LYMPHOMA AFTER AXICABTAGENE CILOLEUCEL**
Speth, K., Tiwari, G., Adhikary, S., Song, Q., Chou, J., Locke, F., Jacobson, C., Miklos, D., Oluwole, O., Kersten, M., Topp, M., Kim, J., Bot, et al
BMJ PUBLISHING GROUP.2022: A717
- **BASECAMP-1: LEVERAGING HLA LOSS OF HETEROZYGOSITY IN SOLID TUMORS BY NGS TO IDENTIFY PATIENTS WITH RELAPSED SOLID TUMORS FOR FUTURE CEA AND MSLN LOGIC-GATED TMD (TM) CAR T-CELL THERAPY**
Simeone, D., Morelli, M., Hecht, J., Patel, S., Fakhri, M., Kirtane, K., Welling, T., Lau, S., Lin, Y., Borad, M., Garon, E., Larson, S., Kato, et al
BMJ PUBLISHING GROUP.2022: A670
- **MULTIOMICS AND MULTIMODAL ANALYSIS APPROACH TO CONSTRUCT A DIFFUSE LARGE B CELL LYMPHOMA ATLAS OF TUMOR MICROENVIRONMENT FOR PREDICTIVE MODELING**
Mattie, M., Perbost, R., Turcan, S., Danan, C., Locke, F., Neelapu, S., Miklos, D., Jacobson, C., Lekakis, L., Lin, Y., Ghobadi, A., Kim, J., Wang, et al
BMJ PUBLISHING GROUP.2022: A1513
- **Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy** *The Neurohospitalist*
Reveron-Thornton, R., Scott, B. J., Post, D., Finley Caulfield, A., Werbaneth, K., Hovsepian, D. A., Spiegel, J., Miklos, D., Thomas, R. P., Patel, C. B.
2021: 74-79
- **KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2**
Wang, M., Munoz, J., Goy, A., Locke, F., Jacobson, C., Hill, B., Timmerman, J., Holmes, H., Jaglowski, S., Flinn, I., McSweeney, P., Miklos, D., Pagel, et al
SPRINGER NATURE.2020: 41-43

- **A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)**
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Reagan, P., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O., Siddiqi, T., Lin, Y., Crump, M., Kuruvilla, et al
CELL PRESS.2020: 575–76
- **Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.** *Blood*
Neelapu, S. S., Jacobson, C. A., Oluwole, O. O., Munoz, J., Deol, A., Miklos, D., Bartlett, N. L., Braunschweig, I., Jiang, Y., Kim, J. J., Zheng, L., Rossi, J. M., Locke, et al
2020
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
ELSEVIER SCIENCE INC.2020: S106
- **A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel [Axi-Cel]) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)**
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Reagan, P. M., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Crump, M., Kuruvilla, et al
ELSEVIER SCIENCE INC.2020: S232
- **KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study**
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, et al
ELSEVIER SCIENCE INC.2020: S1
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET** *Clinical cancer research: an official journal of the American Association for Cancer Research*
Alam*, I. S., Simonetta*, F.
2020: 1058–68
- **KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.** *The New England journal of medicine*
Wang, M. n., Munoz, J. n., Goy, A. n., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H. n., Jaglowski, S. n., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, et al
2020; 382 (14): 1331–42
- **Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Jain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., Ansell, S. M., Awan, F. T., Burns, et al
2019
- **Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Waller, E. K., Miklos, D., Cutler, C., Arora, M., Jagasia, M. H., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Chang, S., Clow, F., Lal, I. D., Styles, et al
2019
- **Inhibition of Inositol kinase B controls acute and chronic graft-versus-host disease.** *Blood*
Thangavelu, G. n., Du, J. n., Paz, K. G., Loschi, M. n., Zaiken, M. C., Flynn, R. n., Taylor, P. A., Kirchmeier, A. K., Panoskaltis-Mortari, A. n., Luznik, L. n., MacDonald, K. P., Hill, G. R., Maillard, et al
2019

- **Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene CiloleuceL Therapy** *American Society of Hematology*
Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., Sahaf, B., Esfahani, M. S., Spiegel, J. Y., Oak, J., Beygi, S., Jin, M. C., Chabon, et al
2019
- **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
2019; 3 (16): 2454–64
- **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2018
- **Axicabtagene CiloleuceL (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience**
Nastoupil, L. J., Jain, M. D., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M. A., Lekakis, L. J., Reagan, P. M., Oluwole, O. O., McGuirk, J. P., Deol, A., Sehgal, et al
AMER SOC HEMATOLOGY.2018
- **1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)**
Schultz, L. M., Davis, K. L., Baggott, C., Chaudry, C., Marcy, A., Mavroukakis, S., Sahaf, B., Kong, K. A., Muffly, L. S., Kim, S., Meyer, E. H., Fry, T. J., Qin, et al
AMER SOC HEMATOLOGY.2018
- **Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies**
Hossain, N., Sahaf, B., Abramian, M., Spiegel, J. Y., Kong, K., Kim, S., Mavroukakis, S., Oak, J., Natkunam, Y., Meyer, E. H., Frank, M. J., Feldman, S. A., Long, et al
AMER SOC HEMATOLOGY.2018
- **Elevated Axicabtagene CiloleuceL (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
AMER SOC HEMATOLOGY.2018
- **2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene CiloleuceL (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma**
Neelapu, S. S., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, et al
AMER SOC HEMATOLOGY.2018
- **End of Phase 1 Results from Zuma-6: Axicabtagene CiloleuceL (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma**
Jacobson, C. A., Locke, F. L., Miklos, D. B., Herrera, A. F., Westin, J. R., Lee, J., Rossi, J. M., Zheng, L., Avanzi, M. P., Roberts, Z. J., Sun, J.
AMER SOC HEMATOLOGY.2018
- **Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene CiloleuceL (CAR19) Therapy**
Oak, J., Spiegel, J. Y., Sahaf, B., Natkunam, Y., Long, S. R., Hossain, N., Mackall, C. L., Kong, K. A., Miklos, D. B.
AMER SOC HEMATOLOGY.2018
- **Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease.** *Blood*
Paz, K., Flynn, R., Du, J., Qi, J., Luznik, L., Maillard, I., MacDonald, K. P., Hill, G. R., Serody, J. S., Murphy, W. J., Sage, P. T., Sharpe, A. H., Miklos, et al
2018
- **Axicabtagene CiloleuceL in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1**

Locke, F. L., Ghobadi, A., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Jacobsen, E., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Reagan, P. M., Farooq, U., Deol, et al
CIG MEDIA GROUP, LP.2018: S276

- **Detection of Measurable Residual Disease by Next-Generation Sequencing in Paired Blood and Bone Marrow Samples from Patients with Lymphoid Malignancies**

Miklos, D., Muffly, L., Lee, L., Crossley, B.
CIG MEDIA GROUP, LP.2018: S295–S296

- **Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1**

Locke, F. L., Ghobadi, A., Jacobson, C. A., Jacobsen, E., Miklos, D. B., Lekakis, L. J., Braunschweig, I., Oluwole, O. O., Lin, Y., Siddiqi, T., Deol, A., Reagan, P. M., Farooq, et al
CIG MEDIA GROUP, LP.2018: S277–S278

- **Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1**

Rossi, J. M., Galon, J., Turcan, S., Danan, C., Locke, F. L., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., Lekakis, L. J., Lin, Y., Ghobadi, A., Go, W. Y., Bot, et al
AMER ASSOC CANCER RESEARCH.2018

- **Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., Beumer, J. H., Qiu, J., Cerda, K., Le, R., Otani, J. M., Liu, H., Ross, et al
2018; 24 (2): 373–80

- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*

Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffly, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
2017; 23 (10): 1744–48

- **The Biology of Chronic Graft-Versus-Host Disease: a Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.** *Biology of blood and marrow transplantation*

Cooke, K. R., Luznik, L., Sarantopoulos, S., Hakim, F. T., Jagasia, M., Fowler, D. H., van den Brink, M. R., Hansen, J. A., Parkman, R., Miklos, D. B., Martin, P. J., paczesny, s., Vogelsang, et al
2016

- **Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes** *HAEMATOLOGICA*

Nakasone, H., Sahaf, B., Tian, L., Wang, T., Haagenson, M. D., Schoenrock, K., Perloff, S., Ryan, C. E., Wu, F., Spellman, S. R., Lee, S. J., Ritz, J., Miklos, et al
2016; 101 (1): E30–E33

- **Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.** *Haematologica*

Nakasone, H., Remberger, M., Tian, L., Brodin, P., Sahaf, B., Wu, F., Mattsson, J., Lowsky, R., Negrin, R., Miklos, D. B., Meyer, E.
2015; 100 (11): 1477-1485

- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*

Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al
2015; 50 (10): 1286-1292

- **Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.** *British journal of haematology*

Nickel, R. S., Hendrickson, J. E., Yee, M. M., Bray, R. A., Gebel, H. M., Kean, L. S., Miklos, D. B., Horan, J. T.
2015; 170 (2): 247-256

- **Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.** *Blood*

Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., Takahashi, K., Glover, C., Keane, C., Kihira, S., Visser, B., Callahan, J., Kong, et al

2015; 125 (24): 3679-3687

- **Therapeutic benefits targeting B-cells in chronic graft-versus-host disease** *INTERNATIONAL JOURNAL OF HEMATOLOGY*
Nakasone, H., Sahaf, B., Miklos, D. B.
2015; 101 (5): 438-451
- **National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Paczesny, S., Hakim, F. T., Pidala, J., Cooke, K. R., Lathrop, J., Griffith, L. M., Hansen, J., Jagasia, M., Miklos, D., Pavletic, S., Parkman, R., Russek-Cohen, E., Flowers, et al
2015; 21 (5): 780-792
- **ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Logan, A. C., Wang, Z., Alimoghaddam, K., Wong, R. M., Lai, T., Negrin, R. S., Grumet, C., Logan, B. R., Zhang, M., Spellman, S. R., Lee, S. J., Miklos, D. B.
2015; 21 (4): 746-754
- **A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor.** *Biology of blood and marrow transplantation*
Mahadeo, K. M., Weinberg, K. I., Abdel-Azim, H., Miklos, D. B., Killen, R., Kohn, D., Crooks, G. M., Shah, A. J., Kharbanda, S., Agarwal, R., Kapoor, N.
2015; 21 (3): 440-444
- **Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.** *Bone marrow transplantation*
Percival, M. M., Medeiros, B. C., Tian, L. n., Robeson, S. n., Laport, G. G., Johnston, L. J., Shizuru, J. A., Miklos, D. B., Arai, S. n., Weng, W. K., Negrin, R. S., Lowsky, R. n.
2015
- **Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.** *Biology of blood and marrow transplantation*
Logan, A. C., Vashi, N., Faham, M., Carlton, V., Kong, K., Buño, I., Zheng, J., Moorhead, M., Klinger, M., Zhang, B., Waqar, A., Zehnder, J. L., Miklos, et al
2014; 20 (9): 1307-1313
- **Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.** *Bone marrow transplantation*
Fleischhauer, K., Fernandez-Viña, M. A., Wang, T., Haagenson, M., Battiwalla, M., Baxter-Lowe, L. A., Ciceri, F., Dehn, J., Gajewski, J., Hale, G. A., Heemskerck, M. B., Marino, S. R., McCarthy, et al
2014; 49 (9): 1176-1183
- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.
2014; 20 (6): 837-843
- **Clinical impact of H-Y alloimmunity.** *Immunologic research*
Popli, R., Sahaf, B., Nakasone, H., Lee, J. Y., Miklos, D. B.
2014; 58 (2-3): 249-258
- **A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease.** *Blood*
Meyer, E. H., Hsu, A. R., Lilliental, J., Löhr, A., Florek, M., Zehnder, J. L., Strober, S., Lavori, P., Miklos, D. B., Johnson, D. S., Negrin, R. S.
2013; 121 (24): 4955-4962
- **A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease** *BLOOD*
Meyer, E. H., Hsu, A. R., Lilliental, J., Loehr, A., Florek, M., Zehnder, J. L., Strober, S., Lavori, P., Miklos, D. B., Johnson, D. S., Negrin, R. S.
2013; 121 (24): 4955-4962

- **Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf of the Center for International Blood and Marrow Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Dobbelstein, C., Ahn, K. W., Haagenson, M., Hale, G. A., Van Rood, J. J., Miklos, D., Waller, E. K., Spellman, S. R., Fernandez-Vina, M., Ganser, A., Aljurf, M., Bornhaeuser, M., Gupta, et al
2013; 19 (5): 741-745
- **Humoral Immunity to Cytomegalovirus and Chronic Graft-Versus-Host Disease** *VIRAL IMMUNOLOGY*
Namboodiri, A. M., Nietert, P. J., Wadia, P. P., Miklos, D. B., Pandey, J. P.
2012; 25 (4): 338-340
- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al
2012; 47 (4): 581-588
- **Clonally identical Hodgkin's disease develops after allogeneic hematopoietic cell transplant for CLL** *BONE MARROW TRANSPLANTATION*
Tseng, D., Jones, C. D., Anderson, M., Warnke, R., Zehnder, J. L., Miklos, D. B.
2011; 46 (12): 1576-1578
- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
2011; 17 (11): 1679-1687
- **A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFR α antibodies** *BLOOD*
Chen, G. L., Arai, S., Flowers, M. E., Otani, J. M., Qiu, J., Cheng, E. C., McMillan, A., Johnston, L. J., Shizuru, J. A., Miklos, D. B.
2011; 118 (15): 4070-4078
- **Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation** *TRANSPLANTATION*
Porcheray, F., Miklos, D. B., Floyd, B. H., Sarantopoulos, S., Bellucci, R., Soiffer, R. J., Antin, J. H., Alyea, E. P., Ritz, J., Zorn, E.
2011; 92 (3): 359-365
- **The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Dong, L., Wu, T., Gao, Z., Zhang, M., Kan, F., Spellman, S. R., Tan, X., Zhao, Y., Wang, J., Lu, D., Miklos, D., Petersdorf, E., Fernandez-Vina, et al
2011; 17 (8): 1205-1213
- **B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies** *NATURE MEDICINE*
Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yantha, J., Paltser, G., Tsui, H., Wu, P., Davidson, M. G., Alonso, M. N., Leong, H. X., Glassford, A., Caimol, et al
2011; 17 (5): 610-U134
- **Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease** *MOLECULAR & CELLULAR PROTEOMICS*
Butte, A. J., Sigdel, T. K., Wadia, P. P., Miklos, D. B., Sarwal, M. M.
2011; 10 (3)
- **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.
2011; 46 (2): 192-199
- **Recombinant antigen microarrays for serum/plasma antibody detection.** *Methods in molecular biology (Clifton, N.J.)*
Wadia, P. P., Sahaf, B., Miklos, D. B.
2011; 723: 81-104
- **Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors** *BLOOD*

Shaw, P. J., Kan, F., Ahn, K. W., Spellman, S. R., Aljurf, M., Ayas, M., Burke, M., Cairo, M. S., Chen, A. R., Davies, S. M., Frangoul, H., Gajewski, J., Gale, et al

2010; 116 (19): 4007-4015

- **H-Y antibody titers are increased in unexplained secondary recurrent miscarriage patients and associated with low male : female ratio in subsequent live births** *HUMAN REPRODUCTION*
Nielsen, H. S., Wu, F., Aghai, Z., Steffensen, R., van Halteren, A. G., Spierings, E., Christiansen, O. B., Miklos, D., Goulmy, E.
2010; 25 (11): 2745-2752
- **Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., Miklos, D. B.
2010; 150 (5): 637-639
- **Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.** *Proceedings of the National Academy of Sciences of the United States of America*
Müller, A. M., Linderman, J. A., Florek, M., Miklos, D., Shizuru, J. A.
2010; 107 (33): 14721-14726
- **Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Mueller, A. M., Linderman, J. A., Florek, M., Miklos, D., Shizuru, J. A.
2010; 107 (33): 14721-14726
- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
2010; 16 (8): 1145-1154
- **Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements** *JOURNAL OF IMMUNOLOGY*
Boyd, S. D., Gaeta, B. A., Jackson, K. J., Fire, A. Z., Marshall, E. L., Merker, J. D., Maniar, J. M., Zhang, L. N., Sahaf, B., Jones, C. D., Simen, B. B., Hanczaruk, B., Nguyen, et al
2010; 184 (12): 6986-6992
- **Rituximab in hematopoietic cell transplantation** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Arai, S., Miklos, D. B.
2010; 10 (6): 971-982
- **Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation** *BLOOD*
Wadia, P. P., Coram, M., Armstrong, R. J., Mindrinos, M., Butte, A. J., Miklos, D. B.
2010; 115 (10): 2077-2087
- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
2009; 114 (5): 1099-1109
- **Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Li, L., Wadia, P., Chen, R., Kambham, N., Naesens, M., Sigdel, T. K., Miklos, D. B., Sarwal, M. M., Butte, A. J.
2009; 106 (11): 4148-4153
- **B Cells and Transplantation: An Educational Resource** *Tandem Meeting on Biology of Blood and Marrow Transplantation*
Small, T. N., Robinson, W. H., Miklos, D. B.
ELSEVIER SCIENCE INC.2009: 104–13
- **H-Y antibody development associates with acute rejection in female patients with male kidney transplants** *TRANSPLANTATION*
Tan, J. C., Wadia, P. P., Coram, M., Grumet, F. C., Kambham, N., Miller, K., Pereira, S., Vayntrub, T., Miklos, D. B.
2008; 86 (1): 75-81

- **Renal pathology in hematopoietic cell transplantation recipients** *96th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Troxell, M. L., Pilapil, M., Miklos, D. B., Higgins, J. P., Kambham, N.
NATURE PUBLISHING GROUP.2008: 396–406
- **Rituximab for steroid-refractory chronic graft-versus-host disease** *Joint Meeting of the American-Society-for-Blood-and-Marrow-Transplantation/Center-for-International-Blood-and-Marrow-Transplant-Research*
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., Macdonell, R., Pasek, M., Lee, et al
AMER SOC HEMATOLOGY.2006: 756–62
- **Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., Holler, E., Ferrara, Y., Shulman, H., Lee, S. Y., Martin, P., Filipovich, A. H., Flowers, et al
2006; 12 (2): 126-137
- **Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors** *44th Annual Meeting of the American-Society-of-Hematology*
Miklos, D. B., Kim, H. T., Zorn, E., Hochberg, E. P., Guo, L. X., Mattes-Ritz, A., Viatte, S., Soiffer, R. J., Antin, J. H., Ritz, J.
AMER SOC HEMATOLOGY.2004: 353–59